Cambiar Aggressive Value ETF (CAMX)

NYSEARCA: CAMX · Real-Time Price · USD
32.45
+0.15 (0.48%)
At close: Apr 16, 2026, 4:00 PM EDT
32.45
0.00 (0.00%)
After-hours: Apr 16, 2026, 8:00 PM EDT
Assets$62.12M
Expense Ratio0.59%
PE Ratio18.36
Shares Out1.94M
Dividend (ttm)$0.57
Dividend Yield1.76%
Ex-Dividend DateDec 30, 2025
Payout FrequencySemi-Annual
Payout Ratio32.45%
Volume185
Open32.50
Previous Close32.29
Day's Range32.45 - 32.50
52-Week Low27.58
52-Week High34.28
Beta0.79
Holdings30
Inception DateFeb 13, 2023

About CAMX

Fund Home Page

The Cambiar Aggressive Value ETF (CAMX) is an exchange-traded fund that mostly invests in total market equity. The fund is an actively managed, global equity fund. Stock selection and weighting is based on the Issuers strongest belief for long-term capital appreciation. CAMX was launched on Feb 13, 2023 and is issued by Cambiar Funds.

Asset Class Equity
Category Global Large-Stock Value
Region Global
Stock Exchange NYSEARCA
Ticker Symbol CAMX
ETF Provider Cambiar Funds

Top 10 Holdings

45.30% of assets
NameSymbolWeight
Uber Technologies, Inc.UBER5.37%
Elevance Health, Inc.ELV5.02%
Delta Air Lines, Inc.DAL4.82%
Union Pacific CorporationUNP4.64%
ON Semiconductor CorporationON4.44%
Amrize AGAMRZ4.31%
Align Technology, Inc.ALGN4.21%
NXP Semiconductors N.V.NXPI4.20%
Bristol-Myers Squibb CompanyBMY4.17%
Honeywell International Inc.HON4.11%
View More Holdings

Dividend History

Ex-DividendAmountPay Date
Dec 30, 2025$0.4793Jan 7, 2026
Sep 25, 2025$0.0914Sep 26, 2025
Dec 30, 2024$0.3884Jan 7, 2025
Dec 28, 2023$0.1464Jan 5, 2024
Full Dividend History

Performance

CAMX had a total return of 17.24% in the past year, including dividends. Since the fund's inception, the average annual return has been 10.96%.

News

Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly

PDUFA target action date set to 10 June 2026 LUND, Sweden, Jan. 9, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for rev...

3 months ago - PRNewsWire

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1 ≤ 1xULN) vs SoC at baseline Continuous improvement of acromegaly sympt...

1 year ago - PRNewsWire

Cambiar Investors Launches Aggressive Value ETF

DENVER--(BUSINESS WIRE)--Cambiar Investors announces the launch of a new active ETF.

3 years ago - Business Wire